Preferred Label : MALT1 Inhibitor ABBV-525;
NCIt definition : An orally bioavailable inhibitor of mucosa-associated lymphoid tissue lymphoma translocation
protein 1 (MALT1), with potential immunomodulating and antineoplastic activities.
Upon oral administration, MALT1 inhibitor ABBV-525 targets, binds to, and inhibits
the activity of MALT1. This inhibits MALT1-dependent CARD11-BCL10-MALT1 (CBM) signaling,
thereby inhibiting the immunosuppressive function of regulatory T-cells (Tregs) and
upregulating the production of interferon-gamma (IFN-g) by Tregs in the tumor microenvironment
(TME). This results in the inhibition of Janus kinase/signal transducers and activators
of transcription (JAK/STAT) and nuclear factor-kappa B (NF-kB) signaling, induces
apoptosis, and inhibits tumor cell growth. MALT1 belongs to the caspase family of
proteases and is the active component of the CBM signaling complex. It plays an essential
role in mediating the immunosuppressive activities of Tregs, and is overactivated
in certain tumor cells, including non-Hodgkin B-cell lymphomas.;
Molecule name : ABBV 525; ABBV-525;
NCI Metathesaurus CUI : CL1906744;
Origin ID : C199362;
UMLS CUI : C5854417;
Semantic type(s)
- concept_is_in_subset
- has_target
